Scientific Publication

Immunological response to boosted PI-containing second line ART after switching for clinical/immunological criteria is comparable to response to first-line in patients with low CD4 counts in Africa


A group of HIV-infected patients in Uganda and Zimbabwe who did not respond well to first-line antireteoviral therapy (zidovudine/lamivudine plus tenofovir, abacavir or nevirapine) were successfully treated with second-line regimens containing lopinavir/ritonavir – median CD4 cell counts showed a good rate of increase